vx 984 m9831 Search Results


vx 984  (MedChemExpress)
93
MedChemExpress vx 984
Images of colony formation by M059K ( a ) and U251 cells ( b ) treated with the <t>DNA-PK-inhibitors</t> <t>VX-984</t> (left panel; 0, 0.1, 0.5, and 1 µM) and NU-7441 (right panel; 0, 0.5, 1, and 2 µM) and transfected with anti-miR-1193 or anti-miR-NC. c – f Survival fractions were calculated. g – j Cell viability was measured by a CCK8 assay after 4 days of culture. The data are presented as the mean ± SD values from triplicate biological experiments. ** P < 0.01, *** P < 0.005. NS not significant: p > 0.05.
Vx 984, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+984+m9831/VX-984/pmc07393494-48-2-10
Average 93 stars, based on 1 article reviews
vx 984 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
m9831/vx-984  (AstraZeneca ltd)
90
AstraZeneca ltd m9831/vx-984
Images of colony formation by M059K ( a ) and U251 cells ( b ) treated with the <t>DNA-PK-inhibitors</t> <t>VX-984</t> (left panel; 0, 0.1, 0.5, and 1 µM) and NU-7441 (right panel; 0, 0.5, 1, and 2 µM) and transfected with anti-miR-1193 or anti-miR-NC. c – f Survival fractions were calculated. g – j Cell viability was measured by a CCK8 assay after 4 days of culture. The data are presented as the mean ± SD values from triplicate biological experiments. ** P < 0.01, *** P < 0.005. NS not significant: p > 0.05.
M9831/Vx 984, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+984+m9831/m9831+vx+984/pm37580318-376-7-20
Average 90 stars, based on 1 article reviews
m9831/vx-984 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
vx 984 m9831  (Vertex Pharmaceuticals)
86
Vertex Pharmaceuticals vx 984 m9831
Synthesis of <t>VX-984:</t> A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
Vx 984 M9831, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+984+m9831/984+m9831+vx/pmc13244300-165-0-12
Average 86 stars, based on 1 article reviews
vx 984 m9831 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Images of colony formation by M059K ( a ) and U251 cells ( b ) treated with the DNA-PK-inhibitors VX-984 (left panel; 0, 0.1, 0.5, and 1 µM) and NU-7441 (right panel; 0, 0.5, 1, and 2 µM) and transfected with anti-miR-1193 or anti-miR-NC. c – f Survival fractions were calculated. g – j Cell viability was measured by a CCK8 assay after 4 days of culture. The data are presented as the mean ± SD values from triplicate biological experiments. ** P < 0.01, *** P < 0.005. NS not significant: p > 0.05.

Journal: Cell Death & Disease

Article Title: Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs

doi: 10.1038/s41419-020-02812-3

Figure Lengend Snippet: Images of colony formation by M059K ( a ) and U251 cells ( b ) treated with the DNA-PK-inhibitors VX-984 (left panel; 0, 0.1, 0.5, and 1 µM) and NU-7441 (right panel; 0, 0.5, 1, and 2 µM) and transfected with anti-miR-1193 or anti-miR-NC. c – f Survival fractions were calculated. g – j Cell viability was measured by a CCK8 assay after 4 days of culture. The data are presented as the mean ± SD values from triplicate biological experiments. ** P < 0.01, *** P < 0.005. NS not significant: p > 0.05.

Article Snippet: DNA-PKcs inhibitor: VX-984 (HY-19939S) and NU-7441 (HY-11006) were purchased from MedChemExpress (USA).

Techniques: Transfection, CCK-8 Assay

Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.

Journal: RSC Medicinal Chemistry

Article Title: Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation

doi: 10.1039/d6md00119j

Figure Lengend Snippet: Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.

Article Snippet: VX-984 (M9831) is a selective inhibitor of DNA-PK cs , developed by Vertex Pharmaceuticals.

Techniques: Reflux